CN Patent

CN120939250A — 聚谷氨酸化抗叶酸剂及其用途

Assigned to LEAF Holdings Group LLC · Expires 2025-11-14 · 1y expired

What this patent protects

本发明的发明名称是聚谷氨酸化抗叶酸剂及其用途。本公开总体上涉及聚谷氨酸化抗叶酸剂、含有填充有聚谷氨酸化抗叶酸剂的脂质体的制剂、制备聚谷氨酸化抗叶酸剂和含脂质体的制剂的方法,以及使用聚谷氨酸化抗叶酸剂和含脂质体的制剂来治疗骨髓增生性病症(例如癌症)和免疫系统病症(例如自身免疫疾病,如类风湿性关节炎)的方法。

USPTO Abstract

本发明的发明名称是聚谷氨酸化抗叶酸剂及其用途。本公开总体上涉及聚谷氨酸化抗叶酸剂、含有填充有聚谷氨酸化抗叶酸剂的脂质体的制剂、制备聚谷氨酸化抗叶酸剂和含脂质体的制剂的方法,以及使用聚谷氨酸化抗叶酸剂和含脂质体的制剂来治疗骨髓增生性病症(例如癌症)和免疫系统病症(例如自身免疫疾病,如类风湿性关节炎)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN120939250A
Jurisdiction
CN
Classification
Expires
2025-11-14
Drug substance claim
No
Drug product claim
No
Assignee
LEAF Holdings Group LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.